Cadrenal Therapeutics, Inc. Common Stock

Day range

$0.91 – $0.96

Open

$0.95

Prev close

$0.96

Volume

44.19K

Market cap

$3.42M

Shares out

3.57M

P/E

—

P/S

—

P/B

0.84

P/FCF

—

ROE

-282.1%

ROA

-206.6%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Strategic initiativeOct 7, 2026

  The Company’s Board of Directors has authorized the Company to initiate a formal strategic process to evaluate opportunities to maximize the value of the Company and its asset portfolio. Potential opportunities may include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, business combinations, or other strategic transactions.

• Annual meeting resultsSep 29, 2026

  On September 24, 2026, the Company held its 2026 Annual Meeting at which the Company's stockholders voted on the following five (5) proposals... The final voting results for each item of business voted upon at the 2026 Annual Meeting... is set forth below.

• Regulatory decisionAug 31, 2026

  During the Type D meeting, the FDA agreed on an optimized definition of worsening HIT for the primary endpoint, based on progression of thrombotic events through Day 14 of treatment or hospital discharge. Additionally, the FDA agreed to use placebo control in the Phase 3 trial, with existing standard anticoagulation therapeutics for both the CAD-1005 and placebo control arms.

• Strategic initiativeJul 21, 2026

  Cadrenal Therapeutics, Inc. issued a press release announcing a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise and the initiation of a structured process to secure strategic out-licensing, portfolio monetization, or commercial co-development partnerships for its late-stage assets.

• Executive officer departureJul 17, 2026

  On July 14, 2026, Cadrenal Therapeutics, Inc. (the "Company") entered into a confidential separation agreement and general release (the "Separation Agreement"), dated as of July 9, 2026, with James J. Ferguson III, the Company's Chief Medical Officer. As previously reported, on July 7, 2026, Dr. Ferguson advised the Board of Directors of the Company of his decision to resign from his position as Chief Medical Officer of the Company, effective July 31, 2026 (the "Separation Date").

Days to cover

1.1

Short interest

105.95K

Avg volume

98.17K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
  positiveGlobeNewswire Inc.· Mar 12, 2026
• Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
  positiveBenzinga· Dec 11, 2025
• Kuick Research Releases Landmark Study On US Orphan Drug Rare Disease Market Highlighting Investment And Innovation Opportunities Through 2030
  positiveBenzinga· Oct 31, 2025
• Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire
  positiveGlobeNewswire Inc.· Jul 17, 2024
• Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
  Benzinga· Feb 8, 2024